Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
SynBioVen is a venture capital firm founded in early 2022 and based in the United Kingdom. The organization is dedicated to supporting synthetic biology scientists, founders, and startups. SynBioVen believes that synthetic biology will play a crucial role in the next industrial revolution and the transition to a net-zero economy. The firm has quickly established itself in the synthetic biology sector, focusing on early-stage investments.
Currently, SynBioVen manages a portfolio of seven companies and operates from its R&D Hub in West London. The firm collaborates with SynbiCITE and provides access to the London Biofoundry, enhancing its support for startups in synthetic biology. As of now, SynBioVen is actively building its presence in the UK biotech ecosystem, aiming to drive innovation in environmental sustainability.
SynBioVen specializes in early-stage investments in synthetic biology ventures, primarily focusing on pre-seed and seed funding. The firm provides proof of concept (PoC) funding to help startups validate their ideas and technologies. Their investment strategy emphasizes sectors such as biotech and healthcare, with a strong commitment to supporting ventures that contribute to environmental sustainability.
Investors at SynBioVen look for innovative solutions that address pressing environmental challenges. They offer not only financial support but also access to expertise in synthetic biology research, business development, and financing. The collaboration with SynbiCITE and the London Biofoundry further strengthens their investment approach, providing startups with essential resources and networking opportunities.
SynBioVen's portfolio includes seven notable companies that exemplify the firm's focus on synthetic biology and environmental sustainability:
These companies reflect SynBioVen's commitment to advancing synthetic biology solutions that address environmental and health challenges.
Sir David Harding: Founder and CEO of SynBioVen, with extensive experience in investment and entrepreneurship.
Lord David Willetts FRS: Former UK Minister for Universities and Science, bringing a wealth of knowledge in policy and academia.
Prof Richard Kitney OBE: Co-founder of the Imperial College Synthetic Biology Cluster, with expertise in synthetic biology and engineering.
Prof Paul Freemont: Co-founder of the Imperial College Synthetic Biology Cluster, recognized for his contributions to synthetic biology research and development.
To pitch SynBioVen, submit your proposal through their website's contact form.
Since its founding in early 2022, SynBioVen has been actively building its portfolio in the synthetic biology sector. The firm has established collaborations with SynbiCITE and the London Biofoundry to enhance support for startups. As of now, no specific recent investments or exits have been publicly reported.
What are SynBioVen's investment criteria?
SynBioVen invests in early-stage synthetic biology ventures, specifically targeting pre-seed and seed funding stages. The firm seeks innovative solutions that contribute to environmental sustainability and the next industrial revolution.
How can startups apply for funding from SynBioVen?
Startups interested in funding should reach out through SynBioVen's website. They should prepare a detailed pitch that outlines their business model, technology, and potential impact on sustainability.
What makes SynBioVen different from other venture capital firms?
SynBioVen differentiates itself by focusing exclusively on synthetic biology and its applications in biotech and healthcare. The firm provides not only funding but also access to expertise and resources through collaborations with SynbiCITE and the London Biofoundry.
What is the geographic scope of SynBioVen's investments?
SynBioVen primarily invests in startups based in the United Kingdom, focusing on the local biotech ecosystem to drive innovation in synthetic biology.
What kind of post-investment involvement does SynBioVen have?
SynBioVen actively supports its portfolio companies through access to its R&D Hub, expertise in business development, and connections within the synthetic biology community.
What is the typical check size for investments?
While specific check sizes are not disclosed, SynBioVen focuses on providing early-stage funding, which typically ranges from proof of concept to seed funding amounts.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.